首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries
【24h】

Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries

机译:Accoplipopliens动脉中吸收everolimus洗脱生物吸收血管支架的三年结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To investigate the midterm performance of the everolimus-eluting Absorb bioresorbable vascular scaffold (BVS) for the treatment of symptomatic infrapopliteal atherosclerotic disease. Methods: A single-center study prospectively enrolled 48 symptomatic patients (mean age 82.1 +/- 8.0 years; 27 men) between September 2013 and February 2018 to evaluate the Absorb everolimus-eluting BVS system in distal popliteal and tibial lesions. Mean lesion length was 20.1 +/- 10.8 mm. Following predilation, up to 2 BVS were implanted in target lesions in 55 limbs. Clinical and duplex ultrasound follow-up was performed at 1, 3, 6, 12, 24, 36, and 48 months to determine 30-day morbidity and midterm Kaplan-Meier estimates of binary restenosis, clinically-driven target lesion revascularization (CD-TLR), amputation, and mortality. Results: Seventy-one scaffolds were implanted to treat 61 lesions. Technical success was achieved in all patients, with no amputation, death, or target limb bypass surgery within 30 days of the index procedure. There was 1 early thrombotic occlusion of 2 BVS in a previously anticoagulated patient not given antiplatelet medication after the procedure. During a mean follow-up of 24.0 +/- 15.3 months, 11 (23%) patients died; the remaining 37 were available for follow-up. Binary restenosis (50%-75%) was detected in 6 (8%) scaffolds. Primary patency estimates at 12, 24, and 36 months were 92.2%, 90.3%, and 81.1%; freedom from CD-TLR estimates were 97.2%, 97.2%, and 87.3% at the same time points. No late scaffold thrombosis has been observed. The majority of the 55 limbs (51, 93%) were clinically improved; 4 (7%) were unchanged. Thirty-six (92%) of 39 limbs treated for tissue loss achieved complete wound healing, with no major amputation (limb salvage 100%). Conclusion: Midterm follow-up demonstrates excellent safety, patency, and freedom from CD-TLR rates using the Absorb bioresorbable vascular scaffold below the knee.
机译:目的:探讨Everolimus洗脱的中期性能,吸收生物吸收血管支架(BVS)治疗症状侵占动脉粥样硬化疾病。方法:2013年9月和2018年2月在2013年9月至2018年2月期间,单中心研究预先注册了48名症状患者(平均年龄82.1 +/- 8.0岁; 27名男子),以评估在远端流行性和胫骨病变中吸收everolimus洗脱的BVS系统。平均值长度为20.1 +/- 10.8 mm。在55只肢体中植入靶病变中最多2个BV的序列之后。在1,3,6,12,24,36和48个月内进行临床和双重超声跟进,以确定30天的发病率和中期Kaplan-Meier估算二元再生,临床驱动的靶病变血运重建(CD- TLR),截肢和死亡率。结果:植入七十一条支架以治疗61个病变。所有患者都取得了技术成功,在指数程序后30天内没有截肢,死亡,或目标肢体旁路手术。在前面的抗凝患者中有2个BVS的早期血栓形成闭塞,在程序后未给予抗血小板药物。在24.0 +/- 15.3个月的平均随访期间,11名(23%)患者死亡;剩下的37可用于随访。在6(8%)支架中检测到二元再狭窄(50%-75%)。 12,24和36个月的主要通畅估计为92.2%,90.3%和81.1%;与CD-TLR估算的自由度在同一时间点为97.2%,97.2%和87.3%。没有观察到没有晚期支架血栓形成。 55只肢体(51,93%)的大部分临床上改善; 4(7%)不变。治疗组织损失的39只六条(92%)的39只肢体取得了完全伤口愈合,没有重大截肢(肢体救赎100%)。结论:中期随访,使用膝盖下方的吸收生物可吸收的血管支架来表现出优异的安全性,通畅和自由度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号